查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1598726

潰瘍性大腸炎市場：依藥物、疾病、給藥途徑- 全球預測 2025-2030

Ulcerative Colitis Market by Drug (Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors), Disease (Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis), Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年潰瘍性大腸炎市值為74.5億美元，預計2024年將達到81.4億美元，複合年成長率為9.41%，到2030年將達到139.9億美元。

潰瘍性大腸炎（UC）是一種慢性發炎性腸道發炎性腸道疾病，主要涉及結腸最內部的發炎。 UC 對醫療保健市場的影響是巨大的，其盛行率不斷上升，需要有效的治療和管理策略。由於飲食變化、壓力、遺傳和環境觸發因素等因素，UC 的盛行率不斷增加，因此需要解決 UC 問題。因此，隨著診斷和管理醫療設備的進步，對新型治療劑（包括生物製藥、生物相似藥和小分子）的需求不斷增加。最終使用領域包括主要關注胃腸道疾病的醫院、診所和研究機構，旨在改善患者的治療結果和生活品質。影響該市場成長的關鍵因素包括人口老化、診斷方法的改進和產品創新。個人化醫療和標靶治療的最新趨勢，以免疫療法和基因編輯技術的突破為突出，有可能提高治療效果和患者依從性，帶來了巨大的商機。儘管有這些前景光明的趨勢，但市場仍面臨一些限制，例如治療成本高、新興經濟體的認知有限以及嚴格的監管核准程序可能會抑制新開發和商業化。此外，有關副作用和抗藥性的持續挑戰需要持續的研究和創新。完美的創新領域包括非侵入性診斷工具的開發、生技藥品和生物相似藥的進步，以及人工智慧在病患監測和藥物開發中的整合。業務成長機會包括建立藥物開發策略夥伴關係、研究和培養精準健康解決方案以及投資於患者教育計劃。 UC 市場的本質是動態且快速發展的，受到技術進步和對以患者為中心的護理日益關注的推動，因此相關人員需要具有適應性和主動性，以發現新的機會，並保持這一市場極為重要。

主要市場統計
基準年[2023] 74.5億美元
預測年份 [2024] 81.4億美元
預測年份 [2030] 139.9億美元
複合年成長率（%） 9.41%

市場動態：快速發展的潰瘍性大腸炎市場的關鍵市場洞察

供需的動態交互作用正在改變潰瘍性大腸炎市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球潰瘍性大腸炎發生率上升
    • 改善醫療設施並發展藥物開發部門
    • 病患援助計劃和報銷政策的可用性
  • 市場限制因素
    • 原料成本波動
  • 市場機會
    • 持續研發新藥製造
    • 公共和私營部門更多參與生技藥品研究
  • 市場挑戰
    • 政府對生物相似藥核准的嚴格規定

波特五力：開拓潰瘍性大腸炎市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解潰瘍性大腸炎市場的外部影響

外部宏觀環境因素在塑造潰瘍性大腸炎市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解潰瘍性大腸炎市場的競爭格局

潰瘍性大腸炎市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣潰瘍性大腸炎市場供應商的績效評估

FPNV定位矩陣是評估潰瘍性大腸炎市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了潰瘍性大腸炎市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對潰瘍性大腸炎市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球潰瘍性大腸炎的發生率正在上升
      • 加強醫療保健設施並發展藥物開發部門
      • 病患援助計劃和報銷政策的可用性
    • 抑制因素
      • 原料成本波動
    • 機會
      • 新藥生產持續研發
      • 公共和私人組織更多參與生技藥品研究
    • 任務
      • 政府對生物相似藥的核准有嚴格的規定
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章潰瘍性大腸炎藥物市場

  • 發炎藥
  • 抗TNF生物製藥
  • Calcineurin抑制劑
  • 免疫抑制劑

第7章潰瘍性大腸炎市場：依疾病分類

  • 暴發性結腸炎
  • 左側結腸炎
  • 全結腸炎或全身性結腸炎
  • 直腸乙狀結腸炎
  • 潰瘍性直腸炎

第8章潰瘍性大腸炎市場：依給藥途徑

  • 可注射的
  • 口服

第9章北美和南美潰瘍性大腸炎市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區潰瘍性大腸炎市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲潰瘍性大腸炎市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • BioLineRx Ltd
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Circle33, LLC
  • Cosmo Pharmaceuticals NV
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-0335FFDBEF39

The Ulcerative Colitis Market was valued at USD 7.45 billion in 2023, expected to reach USD 8.14 billion in 2024, and is projected to grow at a CAGR of 9.41%, to USD 13.99 billion by 2030.

Ulcerative Colitis (UC) is a chronic inflammatory bowel disease that primarily involves inflammation of the colon's innermost lining. Its impact on the healthcare market is substantial, with a growing prevalence that necessitates effective treatments and management strategies. The necessity of addressing UC lies in its increasing prevalence, driven by factors such as changing dietary habits, stress, genetics, and environmental triggers. This has intensified the demand for novel therapeutics, including biologics, biosimilars, and small molecules, alongside advancements in medical devices for diagnostics and management. Application and end-use sectors primarily include hospitals, clinics, and research institutes focusing on gastrointestinal diseases, aiming to enhance patient outcomes and quality of life. Key factors influencing growth in this market include an aging population, better diagnostic methods, and incremental product innovations. Recent developments in personalized medicine and targeted therapies offer substantial opportunities, underscored by revolutionary breakthroughs in immunotherapies and gene editing technologies which can potentially improve treatment efficacy and patient adherence. Despite these promising trends, the market faces limitations such as high treatment costs, limited awareness in emerging economies, and stringent regulatory approval processes that can stifle new development and commercialization. Furthermore, ongoing challenges with side effects and drug resistance necessitate continuous research and innovation. The best areas for innovation include the development of non-invasive diagnostic tools, advancements in biologics and biosimilars, and the integration of AI in patient monitoring and drug development. Prospects of business growth lie in forging strategic partnerships for drug development, cultivating research in precision health solutions, and investing in patient education initiatives. The nature of the UC market is dynamic and rapidly evolving, driven by technological advancements and a growing emphasis on patient-centric care, making it crucial for stakeholders to remain adaptive and proactive in identifying emerging opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 7.45 billion
Estimated Year [2024] USD 8.14 billion
Forecast Year [2030] USD 13.99 billion
CAGR (%) 9.41%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ulcerative Colitis Market

The Ulcerative Colitis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of ulcerative colitis globally
    • Robust availability of healthcare facilities and evolving drug development sector
    • Availability of patient assistance programs and reimbursement policies
  • Market Restraints
    • Fluctuating cost of raw materials
  • Market Opportunities
    • Ongoing research and development in the production of novel drugs
    • Increasing public and private organization involvement in research of biologics
  • Market Challenges
    • Strict government mandates in approval of biosimilars

Porter's Five Forces: A Strategic Tool for Navigating the Ulcerative Colitis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ulcerative Colitis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ulcerative Colitis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ulcerative Colitis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ulcerative Colitis Market

A detailed market share analysis in the Ulcerative Colitis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ulcerative Colitis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ulcerative Colitis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ulcerative Colitis Market

A strategic analysis of the Ulcerative Colitis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ulcerative Colitis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Bausch Health Companies Inc., BioLineRx Ltd, Boehringer Ingelheim GmbH, Celgene Corporation, Circle33, LLC, Cosmo Pharmaceuticals NV, Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi SA.

Market Segmentation & Coverage

This research report categorizes the Ulcerative Colitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors, and Immunosuppressant.
  • Based on Disease, market is studied across Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis, Proctosigmoiditis, and Ulcerative Proctitis.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of ulcerative colitis globally
      • 5.1.1.2. Robust availability of healthcare facilities and evolving drug development sector
      • 5.1.1.3. Availability of patient assistance programs and reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Fluctuating cost of raw materials
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development in the production of novel drugs
      • 5.1.3.2. Increasing public and private organization involvement in research of biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Strict government mandates in approval of biosimilars
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ulcerative Colitis Market, by Drug

  • 6.1. Introduction
  • 6.2. Anti-Inflammatory Drugs
  • 6.3. Anti-TNF Biologics
  • 6.4. Calcineurin Inhibitors
  • 6.5. Immunosuppressant

7. Ulcerative Colitis Market, by Disease

  • 7.1. Introduction
  • 7.2. Fulminant Colitis
  • 7.3. Left-Sided Colitis
  • 7.4. Pancolitis or Universal Colitis
  • 7.5. Proctosigmoiditis
  • 7.6. Ulcerative Proctitis

8. Ulcerative Colitis Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral

9. Americas Ulcerative Colitis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Ulcerative Colitis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Ulcerative Colitis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. AstraZeneca PLC
  • 4. Bausch Health Companies Inc.
  • 5. BioLineRx Ltd
  • 6. Boehringer Ingelheim GmbH
  • 7. Celgene Corporation
  • 8. Circle33, LLC
  • 9. Cosmo Pharmaceuticals NV
  • 10. Eli Lilly and Company
  • 11. GlaxoSmithKline Plc
  • 12. Johnson & Johnson Services, Inc.
  • 13. Merck & Co., Inc.
  • 14. Mitsubishi Tanabe Pharma Corporation
  • 15. Pfizer Inc.
  • 16. Sanofi SA

LIST OF FIGURES

  • FIGURE 1. ULCERATIVE COLITIS MARKET RESEARCH PROCESS
  • FIGURE 2. ULCERATIVE COLITIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ULCERATIVE COLITIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ULCERATIVE COLITIS MARKET DYNAMICS
  • TABLE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI-TNF BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FULMINANT COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PANCOLITIS OR UNIVERSAL COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, 2023